Summary
Pfizer Inc. filed an 8-K on December 18, 2015, detailing amendments to its By-laws approved by the Board of Directors on December 14, 2015. The most significant change is the implementation of proxy access, allowing eligible shareholders to nominate directors for inclusion in the company's proxy materials. This move to adopt proxy access reflects a responsiveness to shareholder governance preferences and provides a mechanism for long-term shareholders to have a greater voice in board composition. The proxy access provision will become effective for the 2017 annual meeting, and details regarding ownership thresholds, holding periods, and nomination limits are outlined in the amended By-laws.
Key Highlights
- 1Pfizer Inc. has amended its By-laws to adopt proxy access, a significant corporate governance change.
- 2The new proxy access provision allows shareholders to nominate directors to the company's board.
- 3To utilize proxy access, a shareholder or a group of up to 20 shareholders must collectively own at least 3% of Pfizer's outstanding common stock.
- 4The required ownership stake must be held continuously for at least three years.
- 5Eligible shareholders can nominate director candidates constituting up to the greater of two individuals or 20% of the Board.
- 6The proxy access provision will be available for the first time in connection with Pfizer's 2017 annual meeting.
- 7The By-laws were also updated with clarifications to the advance notice bylaw for nominations and other technical adjustments.